Fibrogen announces positive topline results from china pivotal phase 3 clinical trial of roxadustat for the treatment of chemotherapy induced anemia

San francisco and beijing, may 18, 2023 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) and its subsidiary, fibrogen (china) medical technology development co., ltd. today announced positive topline data from company's phase 3 clinical study of roxadustat for treatment of anemia in patients receiving concurrent chemotherapy treatment for non-myeloid malignancies in china.
FGEN Ratings Summary
FGEN Quant Ranking